Individualizing liver transplant immunosuppression using a phenotypic personalized medicine platform

Abstract

Posttransplant immunosuppressive drugs such as tacrolimus have narrow therapeutic ranges. Inter-and intraindividual variability in dosing requirements conventionally use physician-guided titrated drug administration, which results in frequent deviations from the target trough ranges, particularly during the critical postoperative phase. There is a clear need for personalized management of posttransplant regimens to prevent adverse events and allow the patient to be discharged sooner. We have developed the parabolic personalized dosing (PPD) platform, which is a surface represented by a second-order algebraic equation with experimentally determined coefficients of the equation being unique to each patient. PPD uses clinical data, including blood concentrations of tacrolimus-the primary phenotypic readout for immunosuppression efficacy-to calibrate these coefficients and pinpoint the optimal doses that result in the desired patient-specific response. In this pilot randomized controlled trial, we compared four transplant patients prospectively treated with tacrolimus using PPD with four control patients treated according to the standard of care (physician guidance). Using phenotype to personalize tacrolimus dosing, PPD effectively managed patients by keeping tacrolimus blood trough levels within the target ranges. In a retrospective analysis of the control patients, PPD-optimized prednisone and tacrolimus dosing improved tacrolimus trough-level management and minimized the need to recalibrate dosing after regimen changes. PPD is independent of disease mechanism and is agnostic of indication and could therefore apply beyond transplant medicine to dosing for cancer, infectious diseases, and cardiovascular medicine, where patient response is variable and requires careful adjustments through optimized inputs.

Harnessing CURATE.AI as a Digital Therapeutics Platform by Identifying N‐of‐1 Learning Trajectory Profiles

“…In addition, participants were sensitive to these training intensity manipulations, with performance during higher-intensity blocks generally poorer compared to lower-intensity blocks. [43] Importantly, training intensity is also not expected to have a monotonic effect on training improvements. The profiles from individual subjects further demonstrate CU-RATE.AI's potential for optimizing behavioral performance and its rate of improvement.…”

“…If the subject's response to inputs is dynamic, CURATE.AI can constantly re-calibrate the treatment inputs as the subject's response evolves during the course of treatment, resulting in robust and sustainable interventional optimization. [43] Digital therapeutics has emerged as a non-pharmacological alternative for prevention and treatment of cognitive decline and mild dementia, among others. [32][33][34][35][36][37][38][39][40][41][42] Of note, population-based big data sets are not required or utilized for CURATE.AI implementation.…”

Theranostic Nanoparticles for Tracking and Monitoring Disease State

“…A recent clinical study demonstrated that drug synergy and antagonism are dose dependent. 85 This is a major issue that should be considered when designing drug combinations. Drug synergy at the in vitro and preclinical levels may not translate into the clinic.…”

Diamonds, Digital Health, and Drug Development: Optimizing Combinatorial Nanomedicine

“…35 In solid organ transplant immunosuppression, patients are assigned a target range for the blood trough level of tacrolimus. This represents the current standard for assessing the efficacy of immunosuppression.…”